← Eichor
Study identifier: NCT07553247 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Clinical Performance of Laryseal Clear Versus Ambu Aura 40 Laryngeal Mask Airway for Preschool Children

Condition: Supraglottic Airway Devices · Laryseal Clear Laryngeal Mask  ·  Sponsor: Zagazig University

PhaseNA
Planned participants54
Who can joinAll sexes, 3 Years to 6 Years
Healthy volunteersNo

About this study

Preschool children have specific anatomical and physiological characteristics which necessitates careful selection of an appropriate airway management device. Supraglottic airway devices can be used in anticipated or unanticipated difficult airway providing continuous oxygenation and ventilation with less hemodynamic stress response and less postoperative complications. So alternative techniques such as SADs have gained prominence in pediatric anesthesia both as primary airway and as a conduit for endotracheal intubation. So this study will evaluate the clinical performance of Laryseal Clear and Ambu Aura40 laryngeal mask airway in preschool children undergoing surgical procedures.

This description comes directly from the study's public registry record.

Talk to the study team

Rania Kamel, MD  ·  +201229927122  ·  ranion8598@gmail.com

Amany Rabie, MBBCH  ·  +201096414799

Always discuss trial participation with your own doctor first.

Locations (1)

Zagazig university hospitalsZagazig, Sharqia Province, EgyptRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07553247